Inspired by the synthetic lethality induced by loss of BRCA2 and PARP functions, Mendes-Pereira et al. demonstrated that cancers with PTEN deficiency, which also cause HR defects, are sensitive to PARP inhibitors [44]. Here, PTEN is linked to cancer.